Storm Lake Capital
Storm Lake Capital, LLC is a private equity and venture capital firm established in 2007 and headquartered in Troy, Michigan. The firm specializes in incubating and investing in various stages of companies, from seed and startup to mature and distressed assets, primarily focusing on lower middle-market businesses. It targets manufacturing, distribution, and service sectors, with a particular emphasis on metal-forming industries such as automotive, agriculture, aerospace, and heavy equipment. Storm Lake Capital typically invests between $1 million and $10 million in companies with revenues ranging from $10 million to $100 million and EBITDA between $1 million and $20 million. The firm engages in a variety of investment strategies, including minority and majority stakes, management buyouts, and growth funding, and it seeks to maintain an active role on the boards of its portfolio companies. Storm Lake Capital employs its own capital for investments and operates primarily in the Midwest and Central United States.
SciTech Development LLC is a biopharmaceutical company based in Grosse Pointe Farms, Michigan, specializing in oncology drug development. Founded in 2001, the company focuses on creating innovative cancer treatments through its proprietary Drug Delivery Platform (SDP), which employs nanovesicles to enhance drug absorption by cancer cells. SciTech Development's lead product, ST-001, is a triglyceride-free formulation designed to target T-cell lymphoma and small cell lung cancer, among other conditions with limited treatment options. In addition to its main laboratory in Baltimore, Maryland, the company operates a manufacturing facility in Buies Creek, North Carolina, to support its drug development and production efforts.
SciTech Development LLC is a biopharmaceutical company based in Grosse Pointe Farms, Michigan, specializing in oncology drug development. Founded in 2001, the company focuses on creating innovative cancer treatments through its proprietary Drug Delivery Platform (SDP), which employs nanovesicles to enhance drug absorption by cancer cells. SciTech Development's lead product, ST-001, is a triglyceride-free formulation designed to target T-cell lymphoma and small cell lung cancer, among other conditions with limited treatment options. In addition to its main laboratory in Baltimore, Maryland, the company operates a manufacturing facility in Buies Creek, North Carolina, to support its drug development and production efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.